 
                                                    Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells.
Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures.
It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.1M | 
| Three Month Average Volume | 25.2M | 
| High Low | |
| Fifty-Two Week High | 287.5499 USD | 
| Fifty-Two Week Low | 141.975 USD | 
| Fifty-Two Week High Date | 29 Aug 2024 | 
| Fifty-Two Week Low Date | 25 Apr 2024 | 
| Price and Volume | |
| Current Price | 262.69 USD | 
| Beta | 0 | 
| Relative Price Change | |
| Four Week Relative Price Change | -8.60% | 
| Thirteen Week Relative Price Change | 65.36% | 
| Twenty-Six Week Relative Price Change | 56.55% | 
| Fifty-Two Week Relative Price Change | 5.97% | 
| Year-to-Date Relative Price Change | 15.89% | 
| Price Change | |
| One Day Price Change | -8.47% | 
| Thirteen Week Price Change | 76.98% | 
| Twenty-Six Week Price Change | 72.13% | 
| Five Day Price Change | -3.65% | 
| Fifty-Two Week Price Change | 32.79% | 
| Year-to-Date Price Change | 37.24% | 
| Month-to-Date Price Change | 10.62% | 
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -1.75401 USD | 
| Book Value Per Share (Most Recent Quarter) | -0.02396 USD | 
| Tangible Book Value Per Share (Last Fiscal Year) | -1.75401 USD | 
| Tangible Book Value Per Share (Most Recent Quarter) | -0.02396 USD | 
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 1.23941 USD | 
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 14.63734 USD | 
| Revenue Per Share (Trailing Twelve Months) | 18.39359 USD | 
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD | 
| Dividend Per Share (Trailing Twelve Months) | 0 USD | 
| Dividend Per Share (5 Year) | -99999.99 USD | 
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -3.52459 USD | 
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.62848 USD | 
| Normalized (Last Fiscal Year) | -3.52459 USD | 
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -3.52459 USD | 
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.57352 USD | 
| Including Extraordinary Items (Last Fiscal Year) | -3.52459 USD | 
| Including Extraordinary Items (Trailing Twelve Months) | -0.62848 USD | 
| Cash | |
| Cash Per Share (Last Fiscal Year) | 19.39188 USD | 
| Cash Per Share (Most Recent Quarter) | 20.50171 USD | 
| Cash Flow Per Share (Last Fiscal Year) | -3.09183 USD | 
| Cash Flow Per Share (Trailing Twelve Months) | -0.13817 USD | 
| Free Cash Flow Per Share (Trailing Twelve Months) | 2.50175 USD | 
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -54 | 
| Cash Flow Revenue (Trailing Twelve Months) | 14 | 
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -2.63% | 
| Pretax Margin (Last Fiscal Year) | -23.71% | 
| Pretax Margin (5 Year) | -93.92% | 
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 83.02% | 
| Gross Margin (Trailing Twelve Months) | 87.00% | 
| Gross Margin (5 Year) | 83.66% | 
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -15.43% | 
| Operating Margin (Trailing Twelve Months) | 4.38% | 
| Operating Margin (5 Year) | -81.86% | 
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -24.08% | 
| Net Profit Margin (Trailing Twelve Months) | -3.11% | 
| Net Profit Margin (5 Year) | -94.26% | 
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% | 
| Tangible Book Value (5 Year) | -99,999.99% | 
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% | 
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 107.00% | 
| Revenue Growth (3 Year) | 89.45% | 
| Revenue Change (Trailing Twelve Months) | 89.46% | 
| Revenue Per Share Growth | 81.43% | 
| Revenue Growth (5 Year) | 54.80% | 
| Capital Spending Debt | |
| Capital Spending (5 Year) | -13.29% | 
| Total Debt (5 Year) | 102.47% | 
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% | 
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 93.98% | 
| EPS Change (Trailing Twelve Months) | 92.71% | 
| EPS Growth (3 Year) | -99,999.99% | 
| EPS Growth (5 Year) | -99,999.99% | 
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% | 
| EBITDA (5 Year Interim) | -99,999.99% | 
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% | 
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 | 
| Price to Tangible Book (Most Recent Quarter) | -100,000 | 
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 804 | 
| Price to Free Cash Per Share (Trailing Twelve Months) | 106 | 
| Net Debt | |
| Net Debt (Most Recent Quarter) | -1,601,961,000 | 
| Net Debt (Last Fiscal Year) | -1,418,606,000 | 
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 18 | 
| Price to Sales (Trailing Twelve Months) | 14 | 
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 | 
| PE Normalized (Last Fiscal Year) | -100,000 | 
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 | 
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 | 
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 | 
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 | 
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% | 
| Dividend Yield | -99,999.99% | 
| Current Dividend Yield | 0.00% | 
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 | 
| Price to Book (Most Recent Quarter) | -100,000 | 
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 | 
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 | 
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% | 
| Payout Ratio (Trailing Twelve Months) | -99,999.99% | 
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 3 | 
| Quick Ratio (Most Recent Quarter) | 3 | 
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 | 
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 | 
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 | 
| Current Ratio (Most Recent Quarter) | 3 | 
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 41.9M | 
| Free Cash Flow (Trailing Twelve Months) | 318.9M | 
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -2 | 
| Net Interest Coverage (Trailing Twelve Months) | 1 | 
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 | 
| Total Debt to Equity (Most Recent Quarter) | -100,000 | 
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -11.94% | 
| Return on Assets (Trailing Twelve Months) | -1.97% | 
| Return on Assets (5 Year) | -26.56% | 
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% | 
| Return on Equity (Trailing Twelve Months) | -99,999.99% | 
| Return on Equity (5 Year) | -121.69% | 
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -15.61% | 
| Return on Investment (Trailing Twelve Months) | -2.62% | 
| Return on Investment (5 Year) | -32.77% |